Cellular immune response
Mechanism of modulation of T cell responses by N-palmitoylated peptides
Article first published online: 20 OCT 2004
DOI: 10.1002/eji.200425369
Copyright © 2004 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Additional Information
How to Cite
Bueno, C., Lee, Kenneth K., Chau, Luan A., Lee-Chan, E., Singh, B., Strejan, Gill H. and Madrenas, J. (2004), Mechanism of modulation of T cell responses by N-palmitoylated peptides. Eur. J. Immunol., 34: 3497–3507. doi: 10.1002/eji.200425369
Publication History
- Issue published online: 26 NOV 2004
- Article first published online: 20 OCT 2004
- Manuscript Accepted: 10 SEP 2004
- Manuscript Revised: 26 AUG 2004
- Manuscript Received: 11 JUN 2004
- Abstract
- Article
- References
- Cited By
Keywords:
- T lymphocytes;
- TCR;
- Cellular activation;
- Signal transduction;
- Tolerance/Suppression/Anergy
Abstract
Small structural changes in the antigenic peptides recognized by TCR can alter the biological properties of those peptides and convert them into weak agonists, partial agonists, or antagonists of these receptors. These altered peptide ligands (APL) are usually generated by conservative amino acid substitutions at TCR contact residues. Here, we show that APL with therapeutic properties can also be generated by attachment of palmitic acid at the N terminus of the peptide without the need to modify the peptide's primary sequence. Using N-palmitoylated pigeon cytochrome-c peptide 81–104 (PALPCC81–104), we were able to induce T cell hyporesponsiveness to the wild-type peptide in vitro. More importantly, administration of the PALPCC81–104 to mice reduced the responsiveness to the native peptide when tested ex vivo. Biochemical and functional experiments indicated that the action of N-palmitoylated peptides was due to the conversion of the native peptide into a weak agonist that could then induce T cell anergy. Our results demonstrate that N-palmitoylation of antigenic peptides is a feasible strategy to generate APL, as it avoids the need to screen multiple amino acid variants of each specific antigen to identify those with therapeutic properties.

1521-4141/asset/2040_left.gif?v=1&s=92837c2f17424f89abf3f45e2642c107d62e6c04)
1521-4141/asset/EJI_right.gif?v=1&s=bce6d64154702bbe279104b1163baee31019fb77)
1521-4141/asset/cover.gif?v=1&s=1d17f8d1fcad107379391e28980b6bbc7e7758cf)